Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Biosimilar Boom Is Heralded By First Approval

Executive Summary

Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.

You may also be interested in...



Henlius’ Rituximab Results Bolster RA Ambitions In China

Shanghai Henlius Biotech has taken its groundbreaking Chinese rituximab biosimilar a step closer to securing a key rheumatoid arthritis indication.

Henlius Capitalizes On Biosimilar Launches

Henlius has announced plans to expand its global footprint and bolster its manufacturing capacity after seeing its sales shoot up in 2020 based on three new launches.

Henlius Seeks To Add RA Indication To Chinese Rituximab

Shanghai Henlius Biotech has filed with China’s NMPA to add a rheumatoid arthritis indication to its HLX01 approved rituximab biosimilar, despite the originator not being approved for RA in China.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB140122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel